Mankind Pharma Limited IPO
Mankind Pharma Limited was a mainboard IPO in the Pharmaceuticals sector, offered at ₹1,026–₹1,080 per share to raise ₹4,326 crore. The issue was subscribed 15.32× overall (QIBs 49.16×, NIIs 3.8×, retail 0.92×). It listed on 9 May 2023 at ₹1,300 and closed its first day at ₹1,422, a listing gain of +31.7% versus the ₹1,080 issue price. It now trades around ₹2,493 (+130.8% versus the issue price).
Frequently asked questions
- How many times was the Mankind Pharma Limited IPO subscribed?
- The Mankind Pharma Limited IPO was subscribed 15.32× overall — 49.16× in the QIB category, 3.8× among non-institutional investors, 0.92× in retail.
- What were the Mankind Pharma Limited IPO listing gains?
- Mankind Pharma Limited listed on 9 May 2023 at ₹1,300, closing its first day at ₹1,422 — a listing gain of +31.7% versus the ₹1,080 issue price.
- What were the retail allotment odds for the Mankind Pharma Limited IPO?
- Retail was subscribed 0.92×, so a single-lot application had roughly a 100% chance of allotment — most applicants were allotted, and allotment was finalised on 3 May 2023.
- What was the price band and lot size of the Mankind Pharma Limited IPO?
- The price band was ₹1,026–₹1,080 per share, with a minimum lot of 13 shares (₹14,040 at the upper band).
- Who were the registrar and lead manager for the Mankind Pharma Limited IPO?
- KFin Technologies Limited was the registrar, and Kotak Mahindra Capital was the book-running lead manager.